Related Experiment Video

Updated: Mar 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells

Shuntaro Tokunaga1, Tatsuya Nagano2, Kazuyuki Kobayashi1

  • 1Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Anticancer Research
|May 7, 2017
PubMed
Abstract

Insights

Amphiregulin (AREG) drives resistance to amrubicinol (AMR-OH) in lung cancer cells. Targeting AREG with cetuximab can restore sensitivity to amrubicinol, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Amrubicicin (AMR) demonstrates efficacy in lung cancer treatment.
  • Mechanisms of AMR resistance remain largely uncharacterized.
  • Understanding resistance is crucial for optimizing lung cancer therapy.

Purpose of the Study:

  • To investigate the molecular mechanisms of amrubicinol (AMR-OH) resistance in lung cancer.
  • To identify key factors contributing to AMR-OH resistance.
  • To explore potential strategies to overcome AMR-OH resistance.

Main Methods:

  • Development of amrubicinol (AMR-OH)-resistant lung cancer cell lines (H520/R, DMS53/R).
  • Functional analysis using resistant and parent cell lines.
  • Transcriptome analysis to identify differentially expressed genes.
  • Investigating the role of amphiregulin (AREG) using siRNA and conditioned medium.
  • Evaluating the effect of cetuximab in combination with amrubicinol.

Main Results:

  • Amphiregulin (AREG) was significantly upregulated in AMR-OH-resistant cells.
  • Conditioned medium from resistant cells conferred AMR-OH resistance to sensitive cells.
  • siRNA-mediated knockdown of AREG restored AMR-OH sensitivity.
  • Co-administration of cetuximab with amrubicinol resensitized cells to AMR-OH.

Conclusions:

  • Amphiregulin (AREG) is a key mediator of amrubicinol (AMR-OH) resistance in lung cancer.
  • Targeting the EGFR pathway with cetuximab can overcome AMR-OH resistance.
  • These findings suggest novel therapeutic approaches for managing AMR-resistant lung cancer.
Keywords:
Amrubicinamphiregulincetuximablung cancer

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
779
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.7K